33 research outputs found
Rezul'taty ehksperimental'nykh issledovanijj shelushil'no-shlifoval'nojj mashiny dlja zerna
No full textAcute bronchitis: challenges of diagnosis and treatment
No full textInternal medicine specialists often have difficulty in making diagnosis and defining the type of treatment for patients with first time long-lasting cough or newly developed bronchial obstruction syndrome. Acute bronchitis (AB) is one of reasons of cough in patient who survived acute respiratory infection (ARI). The article aims to answer the question of what AB really is and what methods of diagnosis and treatment exist
Emergency treatment of broncial obstruction diseases in outpatient practice
No full textThe most widespread bronchial obstruction diseases are bronchial asthma (BA) and chronic obstructive pulmonary disease (COPD). Exacerbations of asthma and COPD are typically accompanied by acute bronchial obstruction syndrome (BOS). It is common knowledge that first-line drugs in the emergency care of patients with acute BOS are short-acting bronchodilators and glucocorticoids. Short-acting bronchodilators are used in the treatment of exacerbations, to prevent risk of exacerbation or as a symptomatic treatment of BA and COPD, in accordance with clinical and functional symptoms and the course of the disease (controlled, partly controlled, uncontrolled BA) [1]
COMMUNITY AQUIRED PNEUMONIA IN ADULTS: POSSIBILITIES OF TREATMENT IN OUTPATIENT CONDITIONS
No full textCommunity-acquired pneumonia (CAP) is a common and poorly diagnosed disease in the outpatient setting. The decision on hospitalization of the patient or treating him at home is the most important clinical conclusion made by the doctor in the course of the disease. Patients with non-severe course of CAP with the medical point of view are treated on an outpatient basis. Assessment of the severity of the patient CAP is based on the predictive Confusion-Respiratory rate – Blood pressure (CRB)-65 and criteria of systemic inflammatory response syndrome (SVR). CAP patients with a scale CRB 65 score 1 or more and/or syndrome SVR are hospitalized on an emergency basis. In accordance with the national guidelines for VAP amoxicillin is used to treat uncomplicated CAP as monotherapy (Group 1 included CAP patients). Amoxicillin is stable in an acidic environment and food intake doesn’t affect the drug absorption. Amoxicillin binds to plasma proteins by about 20% and easily permeates through histohematic barriers. The drug is active against aerobic gram-positive respiratory Staphylococcus spp. (except those strains producing penicillinase), Streptococcus pneumoniae and aerobic gram-negative respiratory organisms (Haemophilus influenzae, Escherichia coli, some strains of Klebsiella)
Macrolides and their role in the treatment of community-acquired pneumonia of various etiology
No full textThe success of antibiotic therapy depends on the correct choice of antibiotic, timely administration, conditions of the host (patient) and microorganism (bacterial pathogen resistance to a drug), bioavailability and bioequivalence. The latter refers to generic drugs which are very well represented in the domestic pharmacological market
GASTROESOPHAGEAL REFLUX: NEW THERAPEUTIC PROSPECTS
No full textThe article provides the data of epidemiologic studies on frequency of symptoms of the gastroesophageal reflux disease (GERD), risk factors and GERD manifestations. Special emphasis is made on the individual therapeutic approach and choice of the modern effective drug for therapy – PPI Dexlansoprazol
Infusion therapy for chronic liver diseases
No full textAim of review. To present modern options of comprehensive infusion therapy at various liver diseases, indications and contraindications for application of basic blood substitute groups, and pathogenically justified approaches for their use. Summary. Chronic and acute liver diseases are associated to end the genius intoxication, electrolyte disorders, shift of acid-base state, tissue and cellular hypoxia. Infusion therapy with application of modern plasma substitute solutions provide increase in treatment efficacy for this group of patients. Application of basic group infusion solutions along with complex anti-hypoxia agents helps to correct water and electrolyte imbalance as well as disorders of acid-base state, carry out body detoxication, normalize blood pressure, treat edema and ascites syndrome, protein-energy malnutrition, prevent renal value and other complications in liver cirrhosis patients. Comprehensive treatment of liver diseases includes application of modern infusion agents (anti-hypoxia/anti-oxidation) containing pharmacologically active metabolic substances that include succinate-containing drugs developed on the basis of succinic acid and its salts. Succinic acid is presumed to act as the paracrine agent produced by damage hepatocytes (e.g. at ischemia), affecting pericytes (Ito's cell) in the liver through SUCNR1receptors. It results activation of pericytes providing synthesis of extracellular matrix components that are involved in metabolism and regeneration of liver parenchyma cells. Conclusion. Addition of succinic acid-based medications to infusion therapy program for chronic liver diseases provides alleviation of basic clinical syndromes (intoxication, asthenic and autonomous nervous disorders, dyspeptic, cholestatic), and at patients with hepatocellular failure improvement of protein-synthetic liver function
Преимущества порошковой ингаляционной системы HandiHaler® при лечении хронической обструктивной болезни легких различной тяжести
No full text.
Functional and Radiological Assessment of the Respiratory System in Patients with Impaired Lung Diffusion Capacity in the Post-COVID Period
No full textThe objective: to evaluate functional and radiological data of the respiratory system assessment in patients with impaired lung diffusion capacity in the post-COVID period.Subjects and Methods. Clinical, functional and radiological data were analyzed and compared in the patients divided into two groups according to the degree of lung diffusion capacity (LDC) impairment measured by carbon monoxide (Dlco) after 180 (135–196) days from the onset of acute symptoms of COVID-19: Group 1 included patients with Dlco of 80–60%, and Group 2 included patients with Dlco less than 60%. The lung functions were assessed by spirometry, body plethysmography and the Dlco level measurement. The data of CT scans of patients performed in the acute period of COVID-19, after 93 (89–103) days and 180 (135–196) days from the onset of acute symptoms were analyzed.Results. The patients of Group 2 developed a severe form of COVID-19 statistically significantly more often, they required high-flow oxygen therapy (HFO) and stayed in the intensive care unit (ICU): 13/20 (65%), 11/20 (55%), 10/20 (50%) versus 8/24(33,3%), 2/24 (8,3%) and 3/24 (13,5%) in the patients of Group 2, respectively. The level of Dlco (%) after 93 (89–103) days and 180 (135–196) days in Groups 1 and 2 made 66 (64–71) and 71 (67–73) versus 45 (41–53) and 51(47–58), respectively (p<0,05). Honeycombing changes in the lungs were detected by chest CT only in the patients of Group 2 – 16.7% on 93 (89–103) and 180 (135–196) days of observation, respectively.Conclusion. A severe form of COVID-19, stay in the ICU and additional oxygen support are the factors indicating an unfavorable functional state of the respiratory system and presence of irreversible changes in the lung tissue in the post-COVID period
